Non-Invasive Prenatal Testing (NIPT) Market is expected to foresee significant growth. Asia-Pacific to lead the growth!
- Vikas Kumar
- April 1, 2022
- HEALTHCARE, NEWS
- Non-Invasive Prenatal Testing (NIPT) Market Growth, Non-Invasive Prenatal Testing (NIPT) Market news, Non-Invasive Prenatal Testing (NIPT) Market share, Non-Invasive Prenatal Testing (NIPT) Market Size, Non-Invasive Prenatal Testing (NIPT) Market Trend
- 0 Comments
Non-Invasive Prenatal Testing (NIPT) Market is expected to grow at a CAGR of around 14.7% during the forecast period 2021-2027. The market stood at around US$ XX billion in 2020. The high risk of chromosomal abnormalities with increasing maternal age, a growing preference for non-invasive techniques over invasive methods, and an improving reimbursement scenario for NIPT are the crucial factors driving the market growth. Several established players as well as new start-ups are looking for funding to conduct research and clinical testing on NIPT techniques. Many government and private organizations are keenly looking for research institutes and start-ups for the development of innovative testing procedures to detect key genetic disorders through NIPT. For instance, in June 2019, Cradle Genomics, a San-Diego-based start-up, raised over US$ 17 Mn in Series A funding carried out to support clinical development, corporate infrastructure, CLIA lab operations, and commercial launch of the tests.
For a detailed analysis of the market drivers browse through https://univdatos.com/report/non-invasive-prenatal-testing-nipt-market/
Overall Non-Invasive Prenatal Testing (NIPT) industry is expected to witness strong and long-term demand, primarily due to the significant investments for genome sequencing by healthcare industry for fulfilling the industry demand and the increasing incidence of genetic disorders. In addition, the outbreak of the COVID-19 pandemic had a slight negative impact on the market growth due to shutdown of many manufacturing units and disruption in supply chain.
Based on application, the market is bifurcated into trisomy detection, microdeletion detection, and others. Among these, trisomy detection accounts for the largest share of the non-invasive prenatal testing (NIPT) market. This segment’s large share and rapid growth can be attributed primarily to factors such as increasing maternal age and the rising incidence of chromosomal abnormalities. It includes birth defects, learning difficulties, and facial deformity. A child with trisomy may also have heart defects as well as vision and hearing problems. Trisomy 21, also known as Down syndrome, is one of the type of trisomy. According to the Centers for Disease Control and Prevention, the most common chromosomal condition diagnosed in the United States in 2019 is down syndrome. Every year, approximately 6,000 babies in the United States are born with Down syndrome. This means that one out of every 700 babies is born with Down syndrome. Hence, the rising incidences of down syndromes is contributing to the overall market growth..
For a detailed analysis of the market segments browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18494
Based on End-User, the market segments into Hospitals & Clinics, Diagnostic Laboratories, and Others. Diagnostic laboratories are the testing facilities where the NIPT test is performed. The labs offer a variety of NIPT testing services based on the needs of the patients. Because of the large number of diagnostic labs/centers that provide NIPT testing products and services, diagnostic laboratories accounts for the largest share of the non-invasive prenatal testing market.
Furthermore, hospitals play a critical role in prenatal testing. It offers in-house testing to in-house patients. It aids in the prompt testing of pregnant patients, resulting in more accurate treatments based on the diagnoses. Therefore, hospitals & clinics are projected to grow substantially during the forecast period.
Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18494
For a better understanding of the market, the report is analyzed based on different regions including North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and Rest of World. North America hold the leading position in the non-invasive prenatal testing (NIPT) market during the forecast period. The increasing adoption of non-invasive prenatal testing in North America is attributed to the surge in the preterm birth rate, rising maternal mortality rate, and increasing prevalence of chromosomal abnormalities. In addition to this, mounting penetration of non-invasive prenatal testing and the burgeoning incidence of down syndrome in newborns are other important factors proliferating the non-invasive prenatal testing (NIPT) market growth. Moreover, the strong geographical foothold of players in the north American countries offering advanced tests has been crucial factor in the driving the adoption of these tests in the U.S. and Canada.
Non-Invasive Prenatal Testing (NIPT) Market Segmentation
Market Insight, by Product
- Instruments
- Ultrasound Devices
- Next-Generation Sequencing Systems
- Polymerase Chain Reaction Instruments
- Microarrays
- Others
- Consumables
- Assay Kits & Reagents
- Disposables
Market Insight, by Method
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
Market Insight, by Application
- Trisomy Detection
- Microdeletion Detection
- Others
Market Insight, by End-User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
Market Insight, by Region
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- UK
- France
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of World
Top Company Profiles
- Illumina, Inc.
- Yourgene Health
- Natera
- F. Hoffmann-La Roche Ltd
- PerkinElmer Inc.
- Laboratory Corporation of America
- Eurofins LifeCodexx GmbH
- Centogene N.V.
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc
